Generic Name: ofatumumab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Novartis

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Arzerra is a monoclonal antibody approved for chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy.

General Info

Arzerra is an antibody that binds to the CD20 receptor on B cells that grow out of control in people with leukemia and lymphoma. This helps immune cells recognize and attack the cancer.


Dosing Info: Arzerra is administered as an intravenous infusion. It may be given weekly, monthly or less often depending on treatment history and other medications used.

Side Effects

Common side effects include infusion reactions, fever, nausea, diarrhea and fatigue. Arzerra can cause depletion of white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Tumor lysis syndrome, or metabolic abnormalities that can occur when many cancer cells are killed at once, is a less common but potentially serious side effect.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 21, 2018